Evidence map›Paper›PMID 35991324›Full record

ArticleCanadian liver journal2018

The 7th Canadian Symposium on Hepatitis C Virus: "Toward Elimination of HCV: How to Get There".

Michael L Cheng, Mohamed S Abdel-Hakeem, Sophie E Cousineau, Jason Grebely, Alison D Marshall, Sahar Saeed, Selena M Sagan, Naglaa H Shoukry, Jordan J Feld, Sonya A MacParland

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Canadian liver journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. The 8Canadian liver journal · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 4 countries.

Michael L ChengMulti-Organ Transplant Program, University Health Network, Toronto, Ontario.
Mohamed S Abdel-HakeemPenn Institute for Immunology, Department of Microbiology, University of Pennsylvania, Philadelphia, Pennsylvania.
Sophie E CousineauDepartment of Microbiology and Immunology, McGill University, Montreal, Quebec.
Jason GrebelyKirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
Alison D MarshallKirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
Sahar SaeedDepartment of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec.
Selena M SaganDepartment of Microbiology and Immunology, McGill University, Montreal, Quebec.
Naglaa H ShoukryCentre de Recherche du Centre hospitalier de l'Université de Montréal, Montreal, Quebec.
Jordan J FeldToronto Centre for Liver Disease, Toronto General Hospital, Toronto, Ontario.
Sonya A MacParlandMulti-Organ Transplant Program, University Health Network, Toronto, Ontario.
McGill University · CAUNSW Sydney · AUCairo University · EGCentre Hospitalier de l’Université de Montréal · CAToronto General Hospital · CAUniversity Health Network · CAUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis C virus (HCV) affects more than 268,000 people in Canada. Both the Canadian Institutes of Health Research and the Public Health Agency of Canada recognize the significant impact of HCV-related liver diseases and supported the establishment of a national hepatitis C research network, the Canadian Network on Hepatitis C (CanHepC). Interferon-free direct-acting antiviral regimens lead to more than 95% cure rates in almost all patients with well-tolerated short-course therapy. However, the goal of eliminating HCV in Canada cannot be fully realized until we overcome the financial, geographical, cultural, and social barriers that affect the entire continuum of care from diagnosis and linkage to care through treatment and prevention of new and reinfections. Current practices face difficulties in reversing HCV-induced immunological defects, expanding treatment to neglected communities, combating reinfections and co-infections, and expediting and simplifying the processes of diagnosis and treatment. As part of its knowledge translation mandate, CanHepC has organized the annual Canadian symposium on hepatitis C since 2012. The theme of this year's symposium, "Toward Elimination of HCV: How to Get There?" focused on identifying the requirements of our therapeutic strategies and health policies for the elimination of HCV in Canada.

Indexed as

behaviouralbiomedicalCanHepCclinicalepidemiologicalhepatitis C virusNCRTP-HepCpublic healthsocial sciencesviral hepatitis

Identifiers

PMID35991324
PMCPMC9203159
OpenAlexW2890070632

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.